ArticleClinical infectious diseases : an official publication of the Infectious Diseases Society of America2023
Global Differences in the Management of Staphylococcus aureus Bacteremia: No International Standard of Care.
Article in Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed, 1 synthesis or guideline pooled it, 40 citations in OpenAlex.
- Female Sex and Mortality in Patients with Staphylococcus aureus Bacteremia: A Systematic Review and Meta-analysis.JAMA network open · 2024Pooled it
- Cefazolin for Methicillin-SusceptibleThe New England journal of medicine · 2026Trial
- Factors Associated with Methicillin-ResistantAntibiotics (Basel, Switzerland) · 2026Article
- Development of a rapid diagnostic test for the cefazolin inoculum effect in methicillin-susceptible Staphylococcus aureus: Cefinase disk direct (CDD) test.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2026Article
- A Scenario-Based Survey of Clinician Recommendations for Follow-Up Blood Cultures in Patients With Varying Risk of Persistent Gram-Negative Bacteremia.Open forum infectious diseases · 2026Article
- Impact of a standardized management protocol and antimicrobial stewardship intervention on mortality and quality of care in Staphylococcus aureus bacteremia: a before-after study.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2026Article
- Methicillin-resistant Staphylococcus aureus.Nature reviews. Disease primers · 2026Review
- Empirical glycopeptide exposure and acute kidney injury during cloxacillin therapy inAntimicrobial agents and chemotherapy · 2026Observational
- mGem: Population genomics ofmBio · 2026Article
- Emerging host-directed strategies for overcoming drug resistance and immune evasion in Staphylococcus aureus infections.Journal of advanced research · 2026Review
- Management of seriousPaediatrics & child health · 2026Article
- Hospital-Onset Bloodstream Infections: Progressive Shift from Methicillin-ResistantJournal of clinical medicine · 2026Article
- Subphenotype- and complication-guided adjunctive fosfomycin versus standard monotherapy inThe Lancet regional health. Europe · 2026Article
- Methicillin-resistant and susceptible Staphylococcus aureus: tolerance, immune evasion and treatment.Nature reviews. Microbiology · 2026Review
- [Staphylococcus aureus bacteremia: the long road to adequate therapy : Recent studies].Innere Medizin (Heidelberg, Germany) · 2026Review
- Analysis of Clinical Subphenotypes in Methicillin-ResistantOpen forum infectious diseases · 2025Article
- Review
- Empiric and targeted antibiotic therapy for bloodstream infections in internal medicine patients in Poland: a three-year analysis in a single centre using the AWaRe classification.Pharmacological reports : PR · 2025Article
- Observational
- Should Microhematuria Be Incorporated into the 2023 Duke-International Society for Cardiovascular Infectious Diseases Minor Immunological Criteria?Antibiotics (Basel, Switzerland) · 2025Article
Corrections and comments
- Commented on by
Authors and funding
11 authors at 5 institutions in 5 countries.
Funding
Abstract
backgroundDespite being the leading cause of mortality from bloodstream infections worldwide, little is known about regional variation in treatment practices for Staphylococcus aureus bacteremia (SAB). The aim of this study was to identify global variation in management, diagnostics, and definitions of SAB.
methodsDuring a 20-day period in 2022, physicians throughout the world were surveyed on SAB treatment practices. The survey was distributed through listservs, e-mails, and social media.
resultsIn total, 2031 physicians from 71 different countries on 6 continents (North America [701, 35%], Europe [573, 28%], Asia [409, 20%], Oceania [182, 9%], South America [124, 6%], and Africa [42, 2%]) completed the survey. Management-based responses differed significantly by continent for preferred treatment of methicillin-susceptible S. aureus (MSSA) and methicillin-resistant S. aureus (MRSA) bacteremia, use of adjunctive rifampin for prosthetic material infection, and use of oral antibiotics (P < .01 for all comparisons). The 18F-FDG PET/CT scans were most commonly used in Europe (94%) and least frequently used in Africa (13%) and North America (51%; P < .01). Although most respondents defined persistent SAB as 3-4 days of positive blood cultures, responses ranged from 2 days in 31% of European respondents to 7 days in 38% of Asian respondents (P < .01).
conclusionsLarge practice variations for SAB exist throughout the world, reflecting the paucity of high-quality data and the absence of an international standard of care for the management of SAB.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.